http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102302475-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e2e7272909daa2750367f72d9383af33 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14 |
| filingDate | 2011-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_276e9cc8bd8cce12f6a08632dd8e08e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8ac9c1015fed6c320404a288153e28fa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_380611720a2b6c92670cc311f9c050aa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_825299bcc832d1e314d4da59b1b965b4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_480701fc8cbdca28d7261168b9ef5d15 |
| publicationDate | 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102302475-B |
| titleOfInvention | Resibufogenin dry powder inhalant and preparation method and application thereof |
| abstract | The invention relates to a dry powder inhalant, in particular to a dry powder inhalant prepared from resibufogenin, a preparation method of the dry powder inhalant, and application of the dry powder inhalant to the preparation of a medicine for treating lung tumor. The resibufogenin dry powder inhalant is characterized by consisting of resibufogenin and a medically acceptable auxiliary material in a mass ratio of 1:0.02-1:100. The dry powder inhalant prepared from the resibufogenin can directly act on the lesion site of the lung, reduces toxic and side reactions, improves the bioavailability of the medicine, can overcome the defects that an oral preparation has slow response, a liver first pass effect, systemic toxic and side effects, low bioavailability and the like, and can solve the problems that an injection is inconvenient to use, low in patient compliance, and the like at the same time. |
| priorityDate | 2011-06-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.